Search | Clinical Trials Finder

Conditions: Myeloproliferative Diseases
Interventions: Ruxolitinib, Pracinostat, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS), Preleukemia, Primary Myelofibrosis, Myeloproliferative Disorders, Bone Marrow Disease, Hematological Disease, Precancerous Conditions, Neoplasms, Leukemia, Neoplasms by Histologic Type, Essential Thrombocytosis
Interventions: Pelabresib, Ruxolitinib; Drug
Lead sponsor: Constellation Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Myelofibrosis (MF)
Interventions: ABBV-744, Navitoclax, Ruxolitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: FEDRATINIB; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more

Conditions: Myelofibrosis
Interventions: Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg; Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 26 more

Conditions: Myelofibrosis, Essential Thrombocythemia, MPN
Interventions: Peptide-based vaccine, Poly ICLC; Drug
Lead sponsor: Marina Kremyanskaya; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
Interventions: Ruxolitinib, Tasquinimod; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Presbyopia
Interventions: Multifocal soft contact lenses, Progressive addition lens spectacles; Device · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 38 Years to 58 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: T-Cell Neoplasm, Lymphoproliferative Disorders
Interventions: Pacritinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more

Conditions: Healthy Volunteers
Interventions: MF-HIIT, MF-only, HIIT-only, Sitting rest; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 10 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Healthy Volunteers
Interventions: MF-HIIT, HIIT-only, MF-only, Sedentary activity; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 8 Years to 12 Years
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Royal Center, Indiana

Conditions: Alcohol Consumption, Fetal Alcohol Syndrome Disorders, Students
Interventions: Self-guided Motivational Intervention, Informational Only; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
Interventions: RO7490677, Ruxolitinib; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 7 more

Conditions: Sezary Syndrome, Mycosis Fungoides
Interventions: Mogamulizumab, LD TSEBT; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Myelofibroses, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Combination AZD1775 with AraC, AZD1775 only; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelofibrosis (MF)
Interventions: Ruxolitinib, Navitoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 33
States / cities: Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more

Conditions: Mycosis Fungoides
Interventions: Mogamulizumab-Kpkc, Phototherapy; Drug · Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Myelofibrosis
Interventions: Obatoclax mesylate (GX15-070MS); Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Anorexia Nervosa
Interventions: Multi-Family Guided Self-Help FBT; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions: Rigosertib, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain Perception
Interventions: TMS (Rapid2, Magstim Corp); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cutaneous T-Cell Lymphoma
Interventions: SGX301 (synthetic hypericin), Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions: Glasdegib (PF-04449913), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more

Search by objective public record fields.

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Multifocal Visual Performance Study

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Acute Effects of High-intensity Interval Training With Mindfulness-based Recovery on Executive Function in Children

Classroom Break, Cognition, and Fitness in Elementary School Children

A Media Based Motivational Intervention to Prevent Alcohol Exposed Pregnancies (AEPs)

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

Multifamily Guided Self-Help Family-Based Treatment (MF-GSH-FBT)

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

The Effect of Transcutaneous Magnetic Stimulation on Acute Pain.

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib